Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.
“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman.
One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.
A comparison of the detection rates for 68Ga-PSMA PET/CT and mpMRI in low, intermediate and high-risk prostate cancer was recently shared by experts in EJNMMI.
Such scans determined the final diagnosis in 54% of patients and were more accurate than CRP and WBC levels for identifying fever origin, according to research published in Scientific Reports.
"The accuracy of PSMA-PET is essential to improve stratification and potentially outcomes both in low-risk and high-risk settings,” a doctor involved in the study explained in the Journal of Nuclear Medicine.
“We showed that risk prediction does not depend on cardiovascular risk scores, stenosis severity or CT calcium scoring," researchers said in the Journal of Nuclear Medicine.